Which diabetes weight loss injection is right for you?

Are these injections actually for diabetes, or for weight loss, and does the distinction matter?

The honest answer is: both, depending on the medicine and the dose. Tirzepatide and semaglutide each hold dual UK licences. At weight-management doses, they are prescribed specifically to reduce body weight; at separate diabetes doses (Ozempic for semaglutide, Mounjaro at its diabetes-specific prescribing), they are used to control blood glucose. The medicines used for both diabetes and weight loss overlap considerably in their mechanism, which is why the two conditions are often discussed together.

This distinction matters practically. If you already have type 2 diabetes and your GP has you on metformin or a sulphonylurea, starting a weight-loss injection dose may alter your blood-glucose response. Some medicines (particularly sulphonylureas) carry a hypoglycaemia risk when combined with GLP-1 receptor agonists, and your prescriber may want to adjust your existing regimen before or shortly after starting. The NHS tirzepatide patient information page notes this interaction clearly. Your GP needs to be informed; at nume, GP notification is part of the clinical process, not an optional extra.

For people without diabetes, these medicines' effect on blood sugar is generally modest and not clinically problematic, but it is part of why a thorough medical history is taken before any prescription is issued. A diabetes weight loss injection is not something a prescriber signs off lightly, nor should they.

Which injection is most relevant for someone with type 2 diabetes who also wants to lose weight?

NICE recommends tirzepatide for weight management in adults with a BMI of 35 or above plus at least one weight-related condition, and type 2 diabetes is specifically listed among those qualifying conditions. The NICE TA1026 recommendations set out the full eligibility criteria, including the lower BMI thresholds that apply for some ethnic backgrounds. In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of around 20–21% at the 15mg dose in adults with obesity, a substantial result that contributed to NICE's recommendation.

Semaglutide (Wegovy) is an alternative, with NICE TA875 recommending it within specialist weight management services. The STEP 1 trial found around 15% average weight reduction over 68 weeks at the 2.4mg dose. Both trials included participants with prediabetes and type 2 diabetes in their broader programme data. If you want to explore the comparative evidence in more detail, the type 2 diabetes weight loss injections page covers this thoroughly.

For people with prediabetes specifically, the picture is encouraging but more nuanced, the considerations for prediabetes deserve their own look, because the clinical framing differs slightly from established type 2 diabetes. A prescriber will factor in your HbA1c trajectory, not just a snapshot BMI figure.

What is uncertain, and who should you talk to before starting?

Several things remain genuinely case-by-case. If your diabetes is well-controlled on existing medication, your prescriber needs to weigh the benefits of adding a weight-loss injection against the complexity of managing two overlapping glucose-lowering pathways. If you use insulin, the interaction is more significant still, the situation for type 1 diabetes is different enough to warrant separate, specialist-level discussion, not a general online consultation.

Pregnancy, breastfeeding, and trying to conceive are clear contraindications. Neither Mounjaro nor Wegovy is recommended during pregnancy or while breastfeeding. The MHRA advises using effective contraception during treatment and for a wash-out period before attempting conception, women taking oral contraceptives should add a non-oral method for the first four weeks of tirzepatide and for four weeks after each dose increase, because the pill's absorption may be reduced. This is not a marginal caveat.

Pancreatitis is a known but infrequent risk with GLP-1 medicines. In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis specifically: seek urgent medical attention for severe, persistent abdominal pain that radiates to the back, with or without vomiting. People with a personal or family history of pancreatitis should raise this with their prescriber before starting. Storing your pen correctly (keeping it in the fridge rather than, say, in the car door where temperatures swing) matters more than it might seem, since an out-of-condition pen may not deliver an accurate dose.

The right person to start with is your GP, especially if you already have a diabetes care plan. A regulated online prescriber, like those at the nume clinical team, can also conduct a thorough same-day review for private treatment, and if you are based in the West Midlands, you can find out more about weight loss injections in Birmingham, including how local access works and what to expect from the assessment process, but that review will always include your diabetes history and any current glucose-lowering medicines as a central part of the assessment, not a footnote.